PREMAL LULLA to Male
This is a "connection" page, showing publications PREMAL LULLA has written about Male.
Connection Strength
0.219
-
Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
Score: 0.029
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.029
-
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
Score: 0.026
-
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib. J Gastrointest Cancer. 2013 Mar; 44(1):98-101.
Score: 0.016
-
Fatal paraneoplastic systemic leukocytoclastic vasculitis as a presenting feature of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S14-6.
Score: 0.014
-
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
Score: 0.010
-
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. Blood Adv. 2025 Mar 11; 9(5):955-965.
Score: 0.009
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.009
-
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
Score: 0.009
-
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
Score: 0.009
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.009
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.007
-
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
Score: 0.007
-
Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
Score: 0.006
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.006
-
Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
Score: 0.006
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.006
-
Retrospective review of extra-pulmonary small cell carcinoma and prognostic factors. Int J Clin Oncol. 2014 Oct; 19(5):822-8.
Score: 0.004
-
Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One. 2013; 8(10):e77409.
Score: 0.004
-
Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate. Int J Clin Oncol. 2011 Dec; 16(6):722-5.
Score: 0.004